Archive for July 2023
Cannara Biotech Inc. Reports Record Q3 2023 Financial Results
Cannara Biotech Inc. has announced its fiscal third quarter 2023 financial and operating results for the three- and nine-month periods ending May 31, 2023. The net revenues were $15.9 million and $39 .3 million, a 57% and 63% increase compared to the same periods of prior year. The company delivered its ninth consecutive quarter of positive Adjusted EBITDA of $3.9 million, a…
Read MoreGemina Laboratories Announces Major Breakthrough in Environmentally Friendly Lateral Flow Test Design by Removing the Requirement for Nitrocellulose
Gemina Laboratories Ltd. has announced another major innovation in lateral flow assay test design resulting from its innovative, patented Gemina Bridge chemistry platform. Gemina Labs has deployed cellulose (paper) test strips in the lateral flow assay format, a fully biodegradable, environmentally friendly alternative to the industry-standard nitrocellulose strip. Gemina Laboratories Ltd., a client of our…
Read MoreViemed Healthcare Announces Date and Time for Conference Call
Viemed Healthcare, Inc. has announced that it will host its Quarterly Conference Call on Thursday, August 10, 2023 at 11:00 a.m. ET. Financial professionals are invited to call in to register in advance to ask questions. Following the live call, a replay will be available in the Investor Relations section of the Company’s website, www.viemed.com.…
Read MoreForaco Provides Notice of 2023 Q2 Results & Conference Call
Foraco International SA will release its second quarter 2023 financial results, prior to TSX market open on Thursday, July 27, 2023 . Following the release, management of the company will host a conference call at 11:00 am ET to review the financial results. The call will be hosted by Tim Bremner , CEO and Fabien…
Read MoreCEMATRIX Announces $5.9 Million in New Contracts
CEMATRIX Corporation has announced it has executed $5.9 million in new contracts to bring total contracts announced since the end of the fiscal year to $27.2 million and $64.2 million since August 3, 2022. The corporation’s total backlog has increased to $99.4 million, a 24.9% increase compared to the sales adjusted backlog of $79.6 million…
Read MoreAdvanced Health Intelligence Ltd: Shareholder Update – FDA and Stellenbosch Study
Advanced Health Intelligence Ltd has provided a shareholder update regarding technology progress and the Stellenbosch University study. The shareholder update aims to offer detailed insight into the ongoing development, launch and release of their BHA, the company’s ground-breaking smartphone-based biometric health assessment. Further details explain the actions the company is taking to launch its robust,…
Read More